{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.21","upperLimit":"1.65","value":"0.60"},{"groupId":"OG001","lowerLimit":"0.28","upperLimit":"3.82","value":"1.10"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"title":"CCNE1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.31","upperLimit":"4.58","value":"0.90"},{"groupId":"OG001","lowerLimit":"0.33","upperLimit":"1.86","value":"0.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"title":"MSI2"}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"26"}],"units":"Participants"}],"description":"Responders were AML participants who achieved CR, CRi, MLFS, PR or PRi based on investigator-reported best overall response and MDS participants who achieved CR, mCR, PR or SD based on investigator-reported best overall response. Whole blood mRNA analyses were performed on 21 mRNA candidates. Ratios of mRNA level to baseline showing statistically significant correlation with clinical response are reported.","dispersionType":"Full Range","groups":[{"description":"AML subjects who achieved CR, CRi, MLFS, PR, or PRi (AML investigator reported best overall response), and MDS subjects who achieved CR, mCR, PR, or SD (MDS investigator reported best overall response).","id":"OG000","title":"Phase 2 Fit (Biomarker, Responder)"},{"description":"AML subjects who did not achieve CR, CRi, MLFS, PR, or PRi; and MDS subjects who did not achieve CR, mCR, PR or SD were defined as non-responders for best overall response.","id":"OG001","title":"Phase 2 Fit (Biomarker, Non-Responder)"}],"paramType":"MEDIAN","populationDescription":"PD analysis set: all enrolled participants in Phase 2 Fit who received at least 1 dose of glasdegib, had at least 1 PD parameter with a baseline and an adequate post treatment assessment.","reportingStatus":"POSTED","timeFrame":"Baseline (Induction Cycle 1/Day -3 pre-dose); End of Treatment (maximum of 12 cycles from start of therapy or until disease progression or relapse, participant refusal or unacceptable toxicity occurred, whichever came first, an average of 1 year)","title":"Ratios of mRNA Levels to Baseline Associated With Best Overall Response at Phase 2 Fit","type":"SECONDARY","unitOfMeasure":"ratio"}